Dr. Stephen Lockhart is Vice President and Head of Europe and Asia-Pacific Vaccine Clinical Research and Development (VCRD) at Pfizer.
Stephen qualified as a physician in 1980. Following training in hospital internal medicine and research, Stephen joined the pharmaceutical industry in 1986. He has over 30 years of experience in pharmaceutical and vaccine development and has extensive experience building and leading teams responsible for strategic and operational aspects of the development, registration and post-marketing support of numerous products. Stephen’s experience spans Europe, North America, China, Japan, Australia, South Africa, Singapore and other markets around the world. His vaccine experience includes senior positions in Vaccine Development at Lederle Praxis Biologicals, Wyeth Vaccine Research, Emergent Biosolutions, Sanofi Pasteur MSD and Pfizer. Stephen has been involved in development of vaccines against influenza, varicella, respiratory syncytial virus, H. Influenzae type b, anthrax, tuberculosis, pneumococcus, meningococcus, Clostridium difficile, Staphylococcus aureus, and typhoid as well as paediatric combination vaccines. He played an instrumental role in clinical development of the first approved polysaccharide protein conjugate vaccine, culminating in a Priz Galien award to Wyeth in the UK.
Steve received his BA and MA from University of Cambridge and BM, BCh and a research based doctoral degree, DM, from the University of Oxford. He received a Diploma in Pharmaceutical Medicine, and is a Member of the Royal College of Physicians (MRCP) and Fellow, Faculty of Pharmaceutical Medicine (FFPM).